Another example are breast cancer patients with high Estrogen Receptor (ER) expression that receive endocrine therapies like ER antagonists or aromatase inhibitors [15,16], or the HER2+ breast and stomach cancers that can be treated with anti-HER2 antibodies [17,18]. Here, ESR1 is linked to breast carcinoma.